Anticoagulants are medications that reduce blood clots and reduce the risk of serious health conditions such as heart attack, diabetes, and others. Blood clots formation occurs due to platelets sticking together and proteins in the blood combining to form a solid mass.In addition,some of the common examples of such drugs include apixaban (Eliquis),dabigatran (Pradaxa), edoxaban (Lixiana), rivaroxaban (Xarelto), and warfarin (Coumadin).The growth of the global anticoagulation marketis driven by the factors such asthe increasing prevalence of venous thromboembolism (VTE) and cardiovascular disorders. In addition, the growing adoption of novel oral anticoagulants (NOACs), the increase in the number of obese and elderly populations, the increasing demand for anticoagulants, and the surge in demand for novel therapeutics are also expected to boost the market growth.However, the high price of NOACs and lack of antidots for NOACs are likely to restrain the market growth.
The anticoagulation market is expected to register a CAGR of 7.80% during the forecast period 2020-2027, to reach USD 31,696.59 million by 2027.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10649
The global anticoagulation market is expected to have a market value ofUSD 31,696.59million by 2027.
Segment Analysis
The global anticoagulation market is segmented into drug class, route of administration, disease indication, distribution channel, and region. The drug class segment has been further segmented into direct oral anticoagulants (DOACs), warfarin,vitamin K,and heparins&Low Molecular Weight Heparin (LMWH). The disease indication segment is further segmented into heart attacks,stroke, Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE), Mechanical Heart Valves (MHV), and others. The route of administration segment has been further segmented into oral, injectable, andothers.The distribution channel segment is segmented into retail pharmacies,hospital pharmacies, andonline pharmacies.
Regional Analysis
The global anticoagulation market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.
The North American market accounted for the largest share in 2019 and is expected to increase at a CAGR of 8.20% during the forecast period. This is due to the rising prevalence of venous thromboembolism (VTE) and cardiovascular disorders, increased risk of a blood clot in various medical conditions, and the adoption of NOACs globally. According to a published article in PubMed in 2019, NOACs have emerged as promising alternatives to Vitamin K Antagonists (VKAs). However, there are some considerations and challenges to their introduction in developing countries.
Europe accounted for a market size of USD 5,205.37million in 2019 and is expected to showa CAGR of 7.26% during the forecast period. Ithas evolved as a prominent market with increased cardiovascular diseases and rising investments in R&D in the pharmaceutical sector. The region has considerable growth potentials that would help expand the global market in the coming years. However, stringent regulations set by various governments are hampering the market growth inthe European region.
The anticoagulation market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Asia-Pacific is expected to showthe highest growth rate during the forecast period from 2020 to 2027. Factors such as an increasing patient population suffering from various chronic and acute diseases, rising prevalence of cardiovascular disease and VTE, developing economies, improving diagnosis rate, and growing demand for ideal therapeuticsare anticipated to boost the market growth. Furthermore, continuous economic development with evolving healthcare infrastructure and improving healthcare awareness have further supported the market's growth. However, increasing treatment expenditure for anticoagulant drugs isanticipated to hamper the market growth in the Asia-Pacificregion.
The Rest of the World is segmented into the Middle East, Africa, and Latin America. The Middle East & Africa region market is expected to witness significant growth due to the increasing number of research companies and subsidiaries involved in R&D activities for anticoagulants.The rising prevalence of cardiovascular disorders in the regionis also influencing the growth of the anticoagulation market.
MRFR recognizes the following companies as the key players in the global anticoagulation market—Pfizer Inc (US), Sanofi (France), Novartis AG (Switzerland), GlaxoSmithKline plc (UK), Daiichi Sankyo Company, Limited, Inc. (Japan), Johnson & Johnson Services Inc (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), andPortola Pharmaceuticals, Inc(US).
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/anticoagulation-market-10649
No comments:
Post a Comment